The main conclusion of the recently completed, landmark Diabetes Control and Complications Trial (DCCT), i. e., the fact that tight control significantly reduces the risk of diabetes-related complications, has been widely acclaimed. This enthusiasm has been fueled in part by the magnitude of the advantage tight control seems to offer: the 2% difference in average HbA1c between the DCCT standard and intensive treatment groups was associated with a 60% reduction in risk for diabetic reti-nopathy, nephropathy, and neuropathy.
No takes yet. Share an insight, caveat, or question.
Rubin et al. (1994) studied this question.